Abstract
Introduction
There have been concerns about prosthesis failure and the potential for systemic toxicity due to release of cobalt and chromium from metal-on-metal hip joint prostheses (MoM-HP). There is conflicting evidence on whether there is a correlation between higher cobalt and chromium concentrations and systemic toxicity.
Methods
We undertook a retrospective review of consecutive patients with MoM-HP referred for outpatient review in toxicology clinics in London, UK, and in the USA recorded in the Toxicology Investigators Consortium (ToxIC) Registry from June 2011 to June 2015.
Results
Thirty-one cases were identified; the median (IQR) serum cobalt concentration was 10.0 (3.8–32.8) mcg/L, and the median (IQR) serum chromium concentration was 6.9 (3.7–18.7) mcg/L. Twenty-three (74.2%) had symptoms, most commonly lethargy, hearing loss, and tinnitus. The odds ratios of symptomatic/asymptomatic patients for metal ion concentrations above/below 7 mcg/L were 1.87 (95% CI 0.37–9.57, p = 0.45) and 0.60 (95% CI 0.10–3.50, p = 0.57) for cobalt and chromium, respectively. Two (6.5%) patients with systemic cobalt toxicity had median (IQR) serum cobalt concentrations significantly higher than those without systemic features (630.4 [397.6–863.2] mcg/L versus 9.8 [2.9–16.4] mcg/L; p = 0.017). However, overall, there were no differences between cobalt (p = 0.38) or chromium (p = 0.92) concentrations between symptomatic and asymptomatic patients and no clinical features or investigation results correlated with cobalt or chromium concentration.
Conclusion
Two (6.5%) of 31 individuals referred for assessment of MoM-HP were diagnosed with systemic cobalt toxicity. However, despite a high prevalence of reported symptoms, neither symptoms nor investigation results correlated with serum cobalt or chromium concentrations.
Similar content being viewed by others
References
Fischer LP, Planchamp W, Fischer B, Chauvin F. The first total hip prostheses in man (1890 - 1960). Hist Sci Med. 2000;34(1):57–70.
Coleman RF, Herrington J, Scales JT. Concentration of wear products in hair, blood, and urine after total hip replacement. Br Med J. 1973;1(5852):527–9.
Paustenbach DJ, Tvermoes BE, Unice KM, Finley BL, Kerger BD. A review of the health hazards posed by cobalt. Crit Rev Toxicol. 2013;43(4):316–62.
Benson MK, Goodwin PG, Brostoff J. Metal sensitivity in patients with joint replacement arthroplasties. Br Med J. 1975;4(5993):374–5.
Evans EM, Freeman MA, Miller AJ, Vernon-Roberts B. Metal sensitivity as a cause of bone necrosis and loosening of the prosthesis in total joint replacement. J Bone Joint Surg Br. 1974;56-B(4):626–42.
Gawkrodger DJ. Metal sensitivities and orthopaedic implants revisited: the potential for metal allergy with the new metal-on-metal joint prostheses. Br J Dermatol. 2003;148(6):1089–93.
Grigoris P, Roberts P, Panousis K, Jin Z. Hip resurfacing arthroplasty: the evolution of contemporary designs. Proc Inst Mech Eng H. 2006;220(2):95–105.
European Commission. The safety of metal-on-metal joint replacements with a particular focus on hip implants. In: (SCENIHR) SCoEaNIHR, editor.: European Union; 2014.
Sampson B, Hart A. Clinical usefulness of blood metal measurements to assess the failure of metal-on-metal hip implants. Ann Clin Biochem. 2012;49(Pt 2):118–31.
Medicines and Health Regulatory Agency (MHRA). Metal-on-metal (MoM) hip replacements—updated advice with patient follow ups. UK Government, 2012. https://www.gov.uk/drug-device-alerts/medical-device-alert-metal-on-metal-mom-hip-replacements-updated-advice-with-patient-follow-ups Accessed 12 July 2017.
Fary C, Thomas GE, Taylor A, Beard D, Carr A, Glyn-Jones S. Diagnosing and investigating adverse reactions in metal on metal hip implants. BMJ. 2011;343:d7441.
Reito A, Lainiala O, Elo P, Eskelinen A. Prevalence of failure due to adverse reaction to metal debris in modern, medium and large diameter metal-on-metal hip replacements—the effect of novel screening methods: systematic review and metaregression analysis. PLoS One. 2016;11(3):e0147872.
National Joint Registry. 12th annual report 2015. 2015.
Australian Orthpaedic Association. Hip and knee arthroplasty, annual report 2015. In: Registry NJR, editor 2015.
U.S. Food and Drug Administration (FDA). Metal-on-metal hip implants: recalls: U.S. Department of Health and Human Services; 2014 [updated 07/02/2014]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241770.htm Accessed 12 July 2017.
U.S Food and Drug Administration (FDA). General recommendations for orthopaedic surgeons after metal-on-metal hip replacement surgery (follow-up): U.S. Department of Health and Human Services; 2015 [updated 04/10/2015]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241667.htm - 3 Accessed 12 July 2017.
Cheung AC, Banerjee S, Cherian JJ, Wong F, Butany J, Gilbert C, et al. Systemic cobalt toxicity from total hip arthroplasties: review of a rare condition part 1—history, mechanism, measurements, and pathophysiology. Bone Joint J. 2016;98-B(1):6–13.
Ding N, Zhou N, Zhou M, Ren GM. Respiratory cancers and pollution. Eur Rev Med Pharmacol Sci. 2015;19(1):31–7.
Brent J, Devlin JJ. Dilemmas about the toxicological consequences of metal-on-metal hip prostheses—what we do and do not know, and what we should do? Clin Toxicol (Phila). 2013;51(4):195–8.
International Agency for Research on Cancer (IARC). Chromium (VI) compounds. In: IARC, editor.: World Health Organisation; 2012. p. 147–67.
Howie DW, Rogers SD, McGee MA, Haynes DR. Biologic effects of cobalt chrome in cell and animal models. Clin Orthop Relat Res. 1996 (329 Suppl):S217–32.
Gessner BD, Steck T, Woelber E, Tower SS. A systematic review of systemic cobaltism after wear or corrosion of chrome-cobalt hip implants. J Patient Saf. 2015;
Bradberry SM, Wilkinson JM, Ferner RE. Systemic toxicity related to metal hip prostheses. Clin Toxicol (Phila). 2014;52(8):837–47.
Zywiel MG, Cherian JJ, Banerjee S, Cheung AC, Wong F, Butany J, et al. Systemic cobalt toxicity from total hip arthroplasties: review of a rare condition part 2. Measurement, risk factors, and step-wise approach to treatment. Bone Joint J. 2016;98-B(1):14–20.
Fox KA, Phillips TM, Yanta JH, Abesamis MG. Fatal cobalt toxicity after total hip arthroplasty revision for fractured ceramic components. Clin Toxicol (Phila). 2016 :1–4.
Mosier BA, Maynard L, Sotereanos NG, Sewecke JJ. Progressive cardiomyopathy in a patient with elevated cobalt ion levels and bilateral metal-on-metal hip arthroplasties. Am J Orthop (Belle Mead NJ). 2016;45(3):E132–5.
Smolders JM, Bisseling P, Hol A, Van Der Straeten C, Schreurs BW, van Susante JL. Metal ion interpretation in resurfacing versus conventional hip arthroplasty and in whole blood versus serum. How should we interpret metal ion data. Hip Int. 2011;21(5):587–95.
Daniel J, Ziaee H, Pynsent PB, McMinn DJ. The validity of serum levels as a surrogate measure of systemic exposure to metal ions in hip replacement. J Bone Joint Surg Br. 2007;89(6):736–41.
MacDonald SJ, Brodner W, Jacobs JJ. A consensus paper on metal ions in metal-on-metal hip arthroplasties. J Arthroplast. 2004;19(8 Suppl 3):12–6.
Van Der Straeten C, Grammatopoulos G, Gill HS, Calistri A, Campbell P, De Smet KA. The 2012 Otto Aufranc award: the interpretation of metal ion levels in unilateral and bilateral hip resurfacing. Clin Orthop Relat Res. 2013;471(2):377–85.
Leikin JB, Karydes HC, Whiteley PM, Wills BK, Cumpston KL, Jacobs JJ. Outpatient toxicology clinic experience of patients with hip implants. Clin Toxicol (Phila). 2013;51(4):230–6.
American College of Medical Toxicology. ACMT-ToxIC background 2016 http://www.acmt.net/ToxIC_Background1.html. Accessed 12 July 2017.
Hart AJ, Quinn PD, Lali F, Sampson B, Skinner JA, Powell JJ, et al. Cobalt from metal-on-metal hip replacements may be the clinically relevant active agent responsible for periprosthetic tissue reactions. Acta Biomater. 2012;8(10):3865–73.
Liow MH, Urish KL, Preffer FI, Nielson GP, Kwon YM. Metal ion levels are not correlated with histopathology of adverse local tissue reactions in taper corrosion of total hip arthroplasty. J Arthroplasty. 2016.
Jantzen C, Jorgensen HL, Duus BR, Sporring SL, Lauritzen JB. Chromium and cobalt ion concentrations in blood and serum following various types of metal-on-metal hip arthroplasties: a literature overview. Acta Orthop. 2013;84(3):229–36.
Back DL, Young DA, Shimmin AJ. How do serum cobalt and chromium levels change after metal-on-metal hip resurfacing? Clin Orthop Relat Res. 2005;438:177–81.
Finley B, Scott PK, Glynn ME, Paustenbach D, Donovan E, Thuett KA. Chromium speciation in the blood of metal-on-metal hip implant patients. Toxicol Environ Chem. 2017;99(1):48–64.
Hartmann A, Hannemann F, Lutzner J, Seidler A, Drexler H, Gunther KP, et al. Metal ion concentrations in body fluids after implantation of hip replacements with metal-on-metal bearing—systematic review of clinical and epidemiological studies. PLoS One. 2013;8(8):e70359.
Hart AJ, Skinner JA, Winship P, Faria N, Kulinskaya E, Webster D, et al. Circulating levels of cobalt and chromium from metal-on-metal hip replacement are associated with CD8+ T-cell lymphopenia. J Bone Joint Surg Br. 2009;91(6):835–42.
Hart AJ, Sabah SA, Bandi AS, Maggiore P, Tarassoli P, Sampson B, et al. Sensitivity and specificity of blood cobalt and chromium metal ions for predicting failure of metal-on-metal hip replacement. J Bone Joint Surg Br. 2011;93(10):1308–13.
Campbell JR, Estey MP. Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory. Clin Chem Lab Med. 2013;51(1):213–20.
U.S. Food and Drug Administration (FDA). Information about soft tissue imaging and metal ion testing: U.S. Department of Health and Human Services; 2016 [updated 08/04/2016]. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm331971.htm Accessed 12 July 2017.
Campbell PA, Kung MS, Hsu AR, Jacobs JJ. Do retrieval analysis and blood metal measurements contribute to our understanding of adverse local tissue reactions? Clin Orthop Relat Res. 2014;472(12):3718–27.
Berber R, Skinner JA, Hart AJ. Management of metal-on-metal hip implant patients: who, when and how to revise? World J Orthop. 2016;7(5):272–9.
Chalmers BP, Perry KI, Taunton MJ, Mabry TM, Abdel MP. Diagnosis of adverse local tissue reactions following metal-on-metal hip arthroplasty. Curr Rev Musculoskelet Med. 2016;9(1):67–74.
Atrey A, Hart A, Hussain N, Waite J, Shepard AJ, Young S. 601 metal-on-metal total hip replacements with 36 mm heads a 5 year minimum year follow up: levels of ARMD remain low despite a comprehensive screening program. J Orthop. 2017;14(1):108–14.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
Jerrold B. Leikin has been a paid consultant of DePuy Companies, which makes metallic hip prostheses since March 2011. Jeffrey Brent was a paid consultant of DePuy Companies from 2012 to 2013 and since 2016 has been a consultant for Stryker Corporation and Smith and Nephew, both of whom make metallic hip prostheses. The other authors report no declarations of interest.
Additional information
Previous presentation of data/abstract:
Ho J, Wax P, Leikin J, Archer JRH, Wood DM, Dargan PI, Brent J. Metal on metal hip joint prostheses: a retrospective case series investigating association of systemic toxicity with serum cobalt and chromium concentrations. Clin Toxicol (Phila) 2016;54:430–1
Oral presentation:
EAPCCT (European Association of Poisons Centres and Clinical Toxicologists) Congress, Madrid, Spain, May 2016
Electronic Supplementary Material
ESM 1
(PDF 73 kb).
Rights and permissions
About this article
Cite this article
Ho, J.H., Leikin, J.B., Dargan, P.I. et al. Metal-on-Metal Hip Joint Prostheses: a Retrospective Case Series Investigating the Association of Systemic Toxicity with Serum Cobalt and Chromium Concentrations. J. Med. Toxicol. 13, 321–328 (2017). https://doi.org/10.1007/s13181-017-0629-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-017-0629-1